Gyre Therapeutics Inc (GYRE)

Between July 2025 and January 2026, Gyre Therapeutics reported its second and third-quarter 2025 financial results and provided business updates. Positive Phase 3 trial results for Hydronidone in liver fibrosis treatment were announced, and patient enrollment was completed in a Phase 3 clinical trial for Pirfenidone Capsules in the treatment of pneumoconiosis. The full-year revenue guidance was revised downwards due to a delayed rollout of Etorel and uncertainties related to government procurement. Alignment with China's CDE on a conditional approval pathway and priority review eligibility for Hydronidone led to a stock price increase. The stock experienced a decline of 41.17% in 2025 but increased by 9.1% in early January 2026.

Information regarding the demand seasonality for Gyre Therapeutics' specific products and services is not explicitly available. However, November has historically shown the highest probability of positive returns for GYRE stock (60%), while March has the lowest (20%).

Gyre Therapeutics is focused on developing and commercializing small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. Its lead candidate, Hydronidone (F351), is focused on treating MASH-associated liver fibrosis in the US and is in Phase 3 in China for chronic Hepatitis B-associated liver fibrosis. Pirfenidone (ETUARY®) is approved in China for idiopathic pulmonary fibrosis and is in Phase 3 studies for other conditions. F573 targets acute-on-chronic liver failure. F528 and F230 are being developed for chronic obstructive pulmonary disease and pulmonary arterial hypertension. Avatrombopag and Nintedanib (Etorel®) are generics approved to be marketed in China. Contiva® is another product in their commercial portfolio in China.

Gyre Therapeutics operates in both the United States and China and is headquartered in San Diego and South San Francisco, California.

Gyre Therapeutics' reputation has been shaped by its progress in clinical trials and regulatory achievements, with positive developments such as favorable Phase 3 trial results for Hydronidone and alignment with China's CDE for conditional approval contributing positively to its standing.

GNI Group Ltd. is the largest shareholder, holding approximately 71% to 72.95% of the company's shares. Public companies collectively own 71% of the stock, while individual investors hold 19%. Institutional shareholders account for 3.21% of ownership, with major institutional owners including Vanguard Group Inc., BlackRock, Inc., Geode Capital Management, Llc, and State Street Corp.